Bio Events Partnering

ERS Genomics

ERS is the world’s leader in licensing of CRISPR/Cas9 technology for a wide variety of applications.
We understand that the licensing situation surrounding CRISPR may seem confusing, but we’re here to help provide information relevant to your specific situation.


Interested in possible use of CRISPR/Cas9 for internal research programs?

  • Are you using modified cells or animals from an academic source? 
  • Are you generating in-house reagents?

Interested in use of genetically modified cells in manufacturing? Including… 

  • mAbs 
  • Gene or cell therapy 
  • Vectors 
  • Industrial enyzmes or intermediates


Do you provide any services which utilize CRISPR/Cas9 or cells or animals modified by the technology? Including…

  • High-throughput screening 
  • Target identification
  • Target validation
  • Cell line development
  • Disease specific cell models
  • Animal models of disease


Do you have an interest in animal health applications? Including… 

  • Disease resistance
  • Vaccines Trait improvements

Let’s schedule a meeting and discuss how ERS might be able to help you.

Schedule a Meeting With ERS.

Your journey with CRISPR begins with a license from ERS Genomics.


Intellectual Property

Knowledge Centre

Contact US

Read More Of Our Articles

Explore more news on CRISPR/Cas9 and how it can provide a leading edge in the highly competitive biotech sector.

Foundational CRISPR/Cas9 gene editing patent granted to CVC in Canada

Dublin, Ireland, January 5, 2023: ERS Genomics announced that its first Canadian patent, CA 2872241, with broad claims to compositions and methods of using CRISPR/Cas9 in humans, animals, plants, and microbes has been granted to the CVC group. CVC stands for University of California, University of Vienna, and Emmanuelle Charpentier and.

Read Full Article

New CRISPR/Cas9 license agreement for ERS Genomics and Cosmo Bio

Dublin, Ireland, December 1, 2022: ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with Cosmo Bio. This is a non-exclusive license agreement granting Japan’s Cosmo Bio access to the ERS CRISPR/Cas9 patent portfolio. ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides.

Read Full Article